KIT and infection: By contrast, the fraction of LineagenegSca1+c-Kit+ (LSK) cells [44], which include MPPs and HSCs, increased by 2-fold on average with imatinib treatment at 66 mg/kg/day, and to an even greater extent with infection (Figs. 3A; S4A and S4B).